Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14660807 | 0.91 | — | — | |
| SCHEMBL15980948 | 0.87 | SLC6A2 (0.40) | ACE2 | |
| SCHEMBL15980960 | 0.82 | SPHK2 (0.41) | — | |
| SCHEMBL15980947 | 0.79 | SLC6A2 (0.44) | — | |
| SCHEMBL15980946 | 0.79 | SLC6A2 (0.44) | — | |
| SCHEMBL15984901 | 0.79 | — | — | |
| SCHEMBL14671688 | 0.78 | — | — | |
| SCHEMBL15980980 | 0.78 | STAT6 (0.40) | — | |
| SCHEMBL15980945 | 0.76 | CCR5 (0.39) | — | |
| SCHEMBL15980950 | 0.76 | CHRM3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9079928-B2 | Methylphenidate-oxoacid conjugates, processes of making and using the same | KEMPHARM, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMT, PNMT, SLC6A3 | PREP 1571/4885ACE2 2313/4885TMEM97 728/4885 |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | PREP 1043/4885ACE2 2206/4885TMEM97 1038/4885 |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | PREP 1043/4885ACE2 2206/4885TMEM97 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.